Loading...
Keywords
Last Name
Institution

Erin M. Guest, MD

TitleHematology/Oncology Pediatrician
InstitutionChildren's Mercy Kansas City
DepartmentPediatrics
Address2401 Gillham Rd
Kansas City MO 64108
ORCID ORCID Icon0000-0003-2482-5608 Additional info
vCardDownload vCard
    Other Positions
    TitleDirector, Cancer Genomics Program
    InstitutionChildren's Mercy Kansas City
    DepartmentPediatrics

    TitleDirector, Cancer Center Biorepository
    InstitutionChildren's Mercy Kansas City
    DepartmentPediatrics

    TitleProfessor
    InstitutionUniversity of Missouri-Kansas City
    DepartmentPediatrics

    TitleResearch Assistant Professor of Pediatrics
    InstitutionUniversity of Kansas Medical Center
    DepartmentPediatrics


    Collapse Biography 
    Collapse education and training
    University of Oklahoma, Norman, OK MD06/2004Medicine
    Children's Mercy Hospital, Kansas City, MOResidency07/2007Pediatrics
    Children's Mercy Hospital, Kansas City, MOFellowship09/2010Pediatric Hematology/Oncology

    Collapse Research 
    Collapse research overview
    Dr. Guest's research areas of focus are in leukemia in infants, cancer genomics, and cancer predisposition syndromes. She is the study chair for the National Cancer Institute sponsored Children's Oncology Group clinical trial for infants with acute lymphoblastic leukemia (ALL) and she leads the national task force on infant ALL. Dr. Guest collaborates with researchers around the world to discover and develop new, more effective therapies for infants with leukemia.
    Collapse research activities and funding
         (Erin Guest)Sep 1, 2017 - Aug 30, 2019
    Children's Mercy Cancer Center Auxiliary Research Fund
    Identifying biomarkers of relapse in infant acute lymphoblastic leukemia (ALL) through single cell sequencing
    Role Description: The aims of this project are to identify and compare the clonal genomic variants and transcript variants of infant ALL with KMT2A rearrangement at initial diagnosis, relapse, and remission. The goal is to determine the pattern of clonal evolution in infant ALL during treatment.
    Role: PI
         (Erin Guest)Jun 1, 2018 - Jun 30, 2019
    Noah's Bandage Project Foundation
    Mechanisms of chemotherapy resistance in pediatric acute lymphoblastic leukemia (ALL) with MLL gene rearrangement (MLL-R)
    Role Description: This project is a bedside to bench translation of a novel therapy for infant ALL, testing DNA demethylation in infants treated with azacitidine on the Children’s Oncology Group trial AALL15P1. The project includes a correlative methylation analysis of MLL rearranged leukemia cells in a mouse xenograft model, pre- and post- treatment with azacitidine.
    Role: PI
         (John Perry)Sep 1, 2018 - Aug 30, 2021
    Braden's Hope Foundation
    Overcoming therapeutic resistance by repurposing a classic chemotherapeutic drug as targeted therapy to reactivate anti-cancer immunity
    Role Description: This translational project is led by Dr. John Perry of Children’s Mercy Research Institute and the specific aims are to identify the pro- vs. anti-cancer cellular immune response to current clinical vs. targeted anthracycline treatment, determine how targeted anthracycline treatment, unlike the clinical dose, eliminates chemoresistant leukemia cells, and define an anti-cancer treatment protocol optimizing anti-tumor immunity while avoiding broad cytotoxicity and resistance.
    Role: Co-PI
         (Midhat Farooqi)Sep 1, 2020 - Aug 31, 2021
    NCI Childhood Cancer Data Initiative, Administrative Supplement for the NCI P30 Cancer Center Support Grant
    Free the Data: Open Sharing of Comprehensive Genomic Childhood Cancer Datasets
    Role Description: The aims of this project are 1) to validate, annotate, and deposit molecular and clinical data into the National Cancer Institute genomic data repository and 2) to share single cell transcriptomic and epigenomic data of diverse pediatric cancers, including new approaches to analytics, data visualization and intuitive data browsing.
    Role: Co-I
    CA190407     (Kathrin Bernt)Sep 1, 2020 - Aug 31, 2023
    Department of Defense Peer Reviewed Cancer Research Program, Translational Team Science Award
    A multi-omics approach to overcome resistance in infant leukemia by identifying immune-therapy failure mechanisms
    Role Description: This project is a multi-institutional collaboration between Dr. Guest and Co-PI’s Dr. David Barrett at Children’s Hospital of Philadelphia and Dr. Patrick Brown at Johns Hopkins University. This work will focus on using new and highly detailed single cell sequencing techniques to study KMT2A-rearranged leukemia in infants and the T-cell function profile in the same patients.
    Role: Co-PI
         (Jennifer Gerton)Jan 1, 2021 - Dec 31, 2021
    University of Kansas Cancer Center, Cancer Biology Program, Clinical/Basic Science Translational Research Pilot Grant Award
    Centromeric DNA instability as a biomarker in Acute Lymphoblastic Leukemia
    Role Description: This study is in collaboration with Dr. Jennifer Gerton, Co-PI and Investigator at Stowers Medical Research Institute. The aim is to determine how patterns of centromere instability correlate with relapse and whether copy number instability is a useful biomarker in ALL.
    Role: Co-PI
    1UG1CA233249-01     (Erin Guest)Jul 1, 2021 - Jun 30, 2022
    Children’s Oncology Group (COG) Hematopoietic Malignancies Integrated Translational Science Center (HM-ITSC) Grant
    Next Generation Sequencing to Detect Minimal Residual Disease in Infant ALL
    Role Description: This project supports next generation sequencing (NGS) of samples from infants enrolled in the COG trial, AALL15P1. The aims are to 1) determine the rate of dominant clone detection by NGS at diagnosis of infant ALL and 2) correlate sequencing-based minimal residual disease with flow cytometry results and event-free survival for infants treated on AALL15P1. The results of this project will impact the design of future trials for infants with ALL.
    Role: PI
         (Erin Guest)Oct 1, 2021 - Sep 30, 2023
    Masonic Cancer Alliance Partners Advisory Board Fund
    Evaluating the Impact of Rare, Clinically Detected Germline Variants in MLL-AF4 Leukemia: A Bedside-to-Bench Translational Model of Infant ALL
    Role Description: In this project, our team proposes to genetically engineer human iPS cells to express MLL-Af4. We will then introduce clinically identified genomic variants using CRISPR, differentiate the cells to CD34+ hematopoietic stem cell precursors, and xenograft into immunodeficient mice. We will assess the cells for clonal outgrowth, serial proliferative capacity, cell surface marker expression, latency of onset and morphologic phenotype of leukemia in xenografts.
    Role: PI
         (Erin Guest)Sep 1, 2023 - Aug 30, 2026
    Braden's Hope Foundation
    Induced pluripotent stem cell models for pediatric KMT2A-r leukemia development and discovery of targeted therapies
    Role Description: In this study, we are advancing an exciting new human induced pluripotent stem cell model of pediatric leukemia for use in understanding the distinct roles of major KMT2A rearrangement-associated oncogenic drivers of pediatric leukemia and testing of novel targeted precision therapies.
    Role: PI
         (Erin Guest)Nov 1, 2023 - Dec 31, 2025
    Noah's Bandage Project Foundation
    A CRISPR genetic screen in an induced pluripotent stem cell model to discover modifiers of therapy-related pediatric leukemia
    Role Description: The aims of this proposal are to develop a high content CRISPR screen for modifiers of KMT2A-r in leukemic progression and to identify genetic changes collaborating with KMT2A-r in driving etoposide-mediated therapy related acute myeloid leukemia.
    Role: PI
         (Carol Fries)Nov 10, 2023 - Oct 31, 2025
    Alex’s Lemonade Stand Reach Grant
    Refining risk stratification for infants with KMT2A-rearranged and KMT2A-germline B-ALL by immunoglobulin high-throughput sequencing analysis of patients enrolled on COG clinical trial AALL15P1
    Role Description: In this project, we will characterize and compare pre-treatment immunoglobulin (Ig) rearrangement composition in infants with KMT2A-rearranged (KMT2A-R) and KMT2A-germline (KMT2A-G) B-ALL, and compare high-throughput sequencing with multiparameter flow cytometry for end of induction MRD detection and relapse prediction in infants with B-ALL.
    Role: Co-PI
         (Kathrin Bernt)Jan 1, 2024 - Dec 31, 2025
    St. Baldrick’s Foundation - American Cancer Society; Childhood Cancer Research RFA: Pilot Accelerator Award
    Venetoclax for infant ALL – COG AALL2321
    Role Description: This is a multi-institution collaboration, led by Dr. Kathrin Bernt, Children’s Hospital of Philadelphia. The aims are 1) functional and epigenomic predictors of clinical response to venetoclax + induction in infants with newly diagnosed ALL and 2) effect of venetoclax + chemotherapy on T-cells from infants with ALL.
    Role: Co-I

    Collapse Bibliography 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Faulk KE, Kairalla JA, Dreyer ZE, Carroll AJ, Heerema NA, Devidas M, Carroll WL, Raetz EA, Loh ML, Hunger SP, Borowitz M, Wang C, Guest E, Brown PA. Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631. Pediatr Blood Cancer. 2023 May 31; e30467. PMID: 37259259.
      View in: PubMed
    2. van Weelderen RE, Klein K, Harrison CJ, Jiang Y, Abrahamsson J, Arad-Cohen N, Bart-Delabesse E, Buldini B, De Moerloose B, Dworzak MN, Elitzur S, Fern?ndez Navarro JM, Gerbing RB, Goemans BF, de Groot-Kruseman HA, Guest E, Ha SY, Hasle H, Kelaidi C, Lapillonne H, Leverger G, Locatelli F, Masetti R, Miyamura T, Nor?n-Nystr?m U, Polychronopoulou S, Rasche M, Rubnitz JE, Stary J, Tierens A, Tomizawa D, Zwaan CM, Kaspers GJL. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-M?nster Study Group. J Clin Oncol. 2023 06 01; 41(16):2963-2974. PMID: 36996387.
      View in: PubMed
    3. Gupta S, Dai Y, Chen Z, Winestone LE, Teachey DT, Bona K, Aplenc R, Rabin KR, Zweidler-McKay P, Carroll AJ, Heerema NA, Gastier-Foster J, Borowitz MJ, Wood BL, Maloney KW, Mattano LA, Larsen EC, Angiolillo AL, Burke MJ, Salzer WL, Winter SS, Brown PA, Guest EM, Dunsmore KP, Kairalla JA, Winick NJ, Carroll WL, Raetz EA, Hunger SP, Loh ML, Devidas M. Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. Lancet Haematol. 2023 Feb; 10(2):e129-e141. PMID: 36725118.
      View in: PubMed
    4. Cheung LC, Aya-Bonilla C, Cruickshank MN, Chiu SK, Kuek V, Anderson D, Chua GA, Singh S, Oommen J, Ferrari E, Hughes AM, Ford J, Kunold E, Hesselman MC, Post F, Faulk KE, Breese EH, Guest EM, Brown PA, Loh ML, Lock RB, Kees UR, Jafari R, Malinge S, Kotecha RS. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy. Leukemia. 2023 01; 37(1):61-71. PMID: 36380143.
      View in: PubMed
    5. Crow J, Samuel G, Farrow E, Gibson M, Johnston J, Guest E, Miller N, Pei D, Koestler D, Pathak H, Liang X, Mangels C, Godwin AK. MicroRNA Content of Ewing Sarcoma Derived Extracellular Vesicles Leads to Biomarker Potential and Identification of a Previously Undocumented EWS-FLI1 Translocation. Biomark Insights. 2022; 17:11772719221132693. PMID: 36341281.
      View in: PubMed
    6. Moskop A, Pommert L, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Guest EM, Breese EH, Schultz LM. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Adv. 2022 07 26; 6(14):4251-4255. PMID: 35580324.
      View in: PubMed
    7. Guest EM, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang CY, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz M, Loh ML, Hunger SP, Brown PA. Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. Haematologica. 2022 05 01; 107(5):1205-1208. PMID: 35172563.
      View in: PubMed
    8. Chen C, Yu W, Alikarami F, Qiu Q, Chen CH, Flournoy J, Gao P, Uzun Y, Fang L, Davenport JW, Hu Y, Zhu Q, Wang K, Libbrecht C, Felmeister A, Rozich I, Ding YY, Hunger SP, Felix CA, Wu H, Brown PA, Guest EM, Barrett DM, Bernt KM, Tan K. Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia. Blood. 2022 04 07; 139(14):2198-2211. PMID: 34864916.
      View in: PubMed
    9. Pollard JA, Guest E, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, Kolb EA, Aplenc R, Meshinchi S, Raimondi SC, Hirsch B, Gamis AS. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2021 10 01; 39(28):3149-3160. PMID: 34048275.
      View in: PubMed
    10. Rao K, Farooki S, Guest E, Chastain K, Gener M, Akangire G. Anaplastic Lymphoma Kinase Inhibitor in Treatment of Inflammatory Myofibroblastic Tumor of the Tongue in Infancy. J Pediatr Hematol Oncol. 2021 05 01; 43(4):e521-e524. PMID: 32769570.
      View in: PubMed
    11. Guest E, Paraskeva N, Griffiths C, Hansen E, Clarke A, Baker E, Harcourt D. The nature and importance of women's goals for immediate and delayed breast reconstruction. J Plast Reconstr Aesthet Surg. 2021 Sep; 74(9):2169-2175. PMID: 33495140.
      View in: PubMed
    12. Perry JM, Tao F, Roy A, Lin T, He XC, Chen S, Lu X, Nemechek J, Ruan L, Yu X, Dukes D, Moran A, Pace J, Schroeder K, Zhao M, Venkatraman A, Qian P, Li Z, Hembree M, Paulson A, He Z, Xu D, Tran TH, Deshmukh P, Nguyen CT, Kasi RM, Ryan R, Broward M, Ding S, Guest E, August K, Gamis AS, Godwin A, Sittampalam GS, Weir SJ, Li L. Overcoming Wnt-?-catenin dependent anticancer therapy resistance in leukaemia stem cells. Nat Cell Biol. 2020 06; 22(6):689-700. PMID: 32313104.
      View in: PubMed
    13. Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clin Cancer Res. 2020 05 15; 26(10):2297-2307. PMID: 31969338.
      View in: PubMed
    14. McAlpine AK, Sauve LJ, Collet JC, Goldfarb DM, Guest E, McDonald PJ, Zheng A, Srigley JA. Risk factors for cerebrospinal fluid shunt infections during an outbreak: a case-control study. J Hosp Infect. 2020 May; 105(1):78-82. PMID: 31870886.
      View in: PubMed
    15. August KJ, Guest EM, Lewing K, Hays JA, Gamis AS. Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib. Pediatr Blood Cancer. 2020 03; 67(3):e28062. PMID: 31724803.
      View in: PubMed
    16. August KJ, Farooki S, Fulbright JM, August A, Portnoy JM, Pommert L, Burke MJ, Guest EM. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. Pediatr Blood Cancer. 2020 01; 67(1):e28021. PMID: 31571395.
      View in: PubMed
    17. Ahmed AA, Vundamati DS, Farooqi MS, Guest E. Precision Medicine in Pediatric Cancer: Current Applications and Future Prospects. High Throughput. 2018 Dec 13; 7(4). PMID: 30551569.
      View in: PubMed
    18. DeSimone RA, Myers GD, Guest EM, Shi PA. Combined heparin/acid citrate dextrose solution A anticoagulation in the Optia continuous mononuclear cell protocol for pediatric lymphocyte apheresis. J Clin Apher. 2019 Aug; 34(4):487-489. PMID: 30489654.
      View in: PubMed
    19. Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang YJ, Kahwash SB, Heerema-McKenney A, Meshinchi S, Gamis AS. Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. Blood. 2017 08 17; 130(7):943-945. PMID: 28674028.
      View in: PubMed
    20. Jones GL, McClellan W, Raman S, Sherman A, Guest E, August K. Parental Perceptions of Obesity and Obesity Risk Associated With Childhood Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2017 07; 39(5):370-375. PMID: 28538500.
      View in: PubMed
    21. Guest EM, Stam RW. Updates in the biology and therapy for infant acute lymphoblastic leukemia. Curr Opin Pediatr. 2017 02; 29(1):20-26. PMID: 27841777.
      View in: PubMed
    22. Kingsmore SF, Petrikin J, Willig LK, Guest E. Emergency medical genomes: a breakthrough application of precision medicine. Genome Med. 2015; 7(1):82. PMID: 26229553.
      View in: PubMed
    23. Radhi M, Fulbright JM, Ginn KF, Guest EM. Childhood cancer for the primary care physician. Prim Care. 2015 Mar; 42(1):43-55. PMID: 25634704.
      View in: PubMed
    24. Ilboudo CM, Guest EM, Ferguson AM, Garg U, Jackson MA. Misleading hepatitis B testing in the setting of intravenous immunoglobulin. F1000Res. 2013; 2:249. PMID: 25075281.
      View in: PubMed
    25. Thornton KM, Nyp MF, Music Aplenc L, Jones GL, Carpenter SL, Guest EM, Shapiro SM, Manimtim WM. An unusual case of rapidly progressive hyperbilirubinemia. Case Rep Pediatr. 2013; 2013:284029. PMID: 24288641.
      View in: PubMed
    26. Luo Z, Lin C, Guest E, Garrett AS, Mohaghegh N, Swanson S, Marshall S, Florens L, Washburn MP, Shilatifard A. The super elongation complex family of RNA polymerase II elongation factors: gene target specificity and transcriptional output. Mol Cell Biol. 2012 Jul; 32(13):2608-17. PMID: 22547686.
      View in: PubMed
    27. Guest EM, Neville KA, Hoyer JD, Safo MK, Garg U, Saunders CJ, Abdulmalik O, Zwick DL. Hb Lake Tapawingo [a46(CE4)Phe?Ser; HBA2:c.140T>C]: a new unstable a chain hemoglobin variant associated with low systemic arterial saturation. Hemoglobin. 2011; 35(4):411-6. PMID: 21797707.
      View in: PubMed
    28. Mohan M, Lin C, Guest E, Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer. 2010 10; 10(10):721-8. PMID: 20844554.
      View in: PubMed
    Guest's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (148) concept(s)
    _
    Co-Authors Expand Description
    See all (10) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department